

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

#### CAPITAL STRUCTURE

ASX code **BDA**  
 Shares on issue **84.2m**  
 Market Capitalisation **~\$56.4m**

#### BOARD & MANAGEMENT

Mr George Livery  
 Executive Chairman

Ms Jo Patterson  
 Chief Executive Officer

Mr Stephen Thompson  
 Executive Director

Mr Akash Bedi  
 Non-Executive Director

Mr Patrice Malard  
 Non-Executive Director

Mr Simon O'Loughlin  
 Non-Executive Director

Mr Simon Taylor  
 Non-Executive Director

Mr Stephen Kelly  
 Company Secretary

#### CONTACT

Level 1, 377 New South Head Rd  
 Double Bay, NSW 2028

## Bod enters UK Market with distribution deal with leading medicine manufacturer PCCA Ltd

- **Agreement with leading medicine manufacturer PCCA Ltd to import and distribute Bod's pharmaceutical grade medicinal cannabis in the UK and Ireland**
- **PCCA are a Specials and MHRA licensed medicines manufacturer with an extensive network of over 4,000 hospitals, clinics, physicians and medical specialists across the UK**
- **In addition to manufacturing and operational expertise, PCCA hold multiple licences including MHRA Specials Manufacturing, Human (MS) and Veterinary (ManSa), Home Office Controlled drugs schedule 2-5 and wholesale dealers authorisation (WDA(H))**
- **These licences ensure that Bod's products can be imported and distributed throughout the region with no regulatory issues**
- **First prescriptions in the UK are expected in the coming months – complements strong growth trajectory in the domestic market**
- **Marks the commencement of Bod's international expansion initiatives – additional export market entries pending**

**Sydney, Australia – 29 July 2019:** Cannabis focused healthcare company, Bod Australia Limited ("Bod", the "Company") (ASX: BDA) has signed a Heads of Agreement with UK Specials medicine manufacturer, PCCA Ltd (PCCA) to import and distribute Bod's pharmaceutical grade medicinal cannabis products, MediCabilis™ throughout the United Kingdom.

PCCA are a leading UK Specials and MHRA licensed medicines manufacturer based in the United Kingdom. The group manufactures a wide range of unlicensed or special medicines to an extensive network of hospitals, pharmacies and clinicians across the UK and Ireland. PCCA UK began in 1999 as a manufacturer of special (known as The Specials Laboratory). PCCA US was established in 1981 as a small network of pharmacists. Together in the UK, US, Canada and Australia PCCA have over 4,000 customers.

Specials medicines are specifically manufactured or obtained to meet a patient's individual clinical need. Special medicines are manufactured or imported under European Good Manufacturing Practice (GMP) standards to ensure patients receive the highest quality products.

The importation process is already underway and Bod expects to receive first prescriptions in the region in the coming months. The Company is witnessing considerable growth in patient numbers for its medicinal cannabis products domestically and is confident the UK will strengthen this revenue profile.

In addition to its manufacturing and operational expertise, PCCA hold multiple licences including MHRA Specials manufacturing, Human (MS) and Veterinary (ManSa), Home Office Controlled drugs schedule 2-5 and Wholesale dealers authorisation (WDA(H)). These licences ensure that Bod's products can be imported and distributed throughout the UK with no regulatory issues.

Further, the licences allow PCCA to manufacture and supply investigational medicinal products to meet supply needs in hospital based clinical trials. Bod and PCCA aim to pursue initiatives around UK clinical trials in the future.

As part of the agreement, Bod will also access PCCA's extensive network of medical specialists and physicians through its Medicinal Cannabis Education Program, which will allow patients greater access to Bod's superior range of clinically validated products.

Bod and PCCA will also collaborate on packaging and distributing other medicinal cannabis products for the UK market.

The agreement is not subject to any material conditions precedent, has no fixed term and can be terminated by the parties by written agreement, or if a material breach of the agreement occurs.

**Bod Australia CEO Jo Patterson said:** "This agreement provides Bod with a strong foundation for growth in the United Kingdom and progresses the Company's rapid European expansion. The UK is an important strategic market entry for the Company and an important one for growth, estimated to be worth €8.8Bn by 2028<sup>1</sup>.

"PCCA are a best in class partner with one of the most extensive distribution networks in Europe. The Company looks forward to working with them and progressing product uptake throughout the region.

"Bod has witnessed considerable growth in its medicinal cannabis business recently with growth in patient numbers."

**PCCA Managing Director Sharon Clift said:** "We are delighted to be working with Bod to import and distribute their products in the UK market, allowing our strong system of medical specialists to provide their patients with access to Bod's products. We look forward to developing our relationship with the team in order to further grow this partnership over the coming years."

- ENDS -

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia's largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

[BODAUSTRALIA.COM](http://BODAUSTRALIA.COM)

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538

<sup>1</sup> Prohibition Partners